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Abstract
The aim of the current study was to evaluate the ex-
pression of ADAM15 disintegrin (ADAM15) in a broad
spectrum of human tumors. The transcript for ADAM15
was found to be highly upregulated in a variety of
tumor cDNA expression arrays. ADAM15 protein ex-
pression was examined in tissue microarrays (TMAs)
consisting of 638 tissue cores. TMA analysis revealed
that ADAM15 protein was significantly increased in
multiple types of adenocarcinoma, specifically in
prostate and breast cancer specimens. Statistical as-
sociation was observed with disease progression
within clinical parameters of predictive outcome for
both prostate and breast cancers, pertaining to
Gleason sum and angioinvasion, respectively. In this
report, we also present data from a cDNA microarray of
prostate cancer (PCa), where we compared transfected
LNCaP cells that overexpress ADAM15 to vector con-
trol cells. In these experiments, we found that ADAM15
expression was associated with the induction of spe-
cific proteases and protease inhibitors, particularly
tissue inhibitor of metalloproteinase 2, as validated
in a separate PCa TMA. These results suggest that
ADAM15 is generally overexpressed in adenocar-
cinoma and is highly associated with metastatic pro-
gression of prostate and breast cancers.
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Introduction
Due to advances in tumor detection, early diagnosis of
human cancer has improved dramatically. Unfortunately,
despite these improvements, some patients who are diag-
nosed early in their disease may still have micrometastasis,
which leads to secondary tumor growth. Thus, the identifi-
cation of early-stage aggressive tumors that are at high risk for
recurrence remains a priority.
The progression of solid tumors to metastatic diseases
includes essential steps that support the detachment of cells
from the surrounding extracellular matrix (ECM), tumor cell sur-
vival, and tissue invasion [1]. One family of proteins supporting
malignant progression is zinc-binding matrix metalloprotein-
ases (MMPs). The role of MMPs in metastatic progression
has been extensively studied in tumor biology. Specific MMPs
have been implicated in the induction of tumor cell migration,
invasion, and angiogenesis. These enzymes contain an active
metalloproteinase domain that catalyzes the degradation of
ECM proteins, such as collagen, laminin, and fibronectin [2].
This activity is believed to mediate the disruption of basement
membrane integrity and to allow cancer cells to invade the
surrounding tissues and vasculature.
Another aspect of proteolytic processing during tumor pro-
gression affects a diverse set of physiologic cell surface proteins,
such asmembrane-anchored growth factors and their receptors,
ectoenzymes, andmany cell adhesionmolecules, including cad-
herins [3]. An intriguing family of membrane metalloproteinases
has been identified in the extracellular processing of these cell
surface molecules. This family of membrane-associated disinte-
grins, referred to as ADAMs (A Disintegrin that contains A
Metalloproteinase), contains modular metalloproteinase motifs,
an integrin-binding domain (disintegrin), and a cysteine-rich
epidermal growth factor–like domain in the extracellular region
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of the molecule. One of the best characterized ADAMs is
tumor necrosis factor convertase (ADAM17), which processes
pro-TNF-a, TNF receptors, interleukin-6 receptor, and amphir-
egulin [4,5]. ADAMs have been implicated in many biologic
processes, including oocyte fertilization, neurogenesis, myo-
genesis, and growth factor shedding [6,7]. Additionally, this
family of disintegrin metalloproteinases has also been shown
to be involved in cancer progression. ADAM10 is over-
expressed in pheochromocytomas and neuroblastomas,
whereas ADAM12 is overexpressed in both breast and
colon cancers [8,9]. ADAM10, ADAM12, and ADAM17
are implicated in gastrointestinal carcinoma [10]. The
multiple domains of these proteinases impart several phys-
iological features, including ECM degradation and shedding of
transmembrane growth factors. ADAM9, ADAM10, ADAM12,
and ADAM17 have been shown to cleave the epidermal
growth factor receptor (EGFR) ligand, heparin-binding (EGF),
leading to transactivation of EGFR. This process has been
implicated in many physiological responses, such as cell
survival, proliferation, and migration, further supporting their
role in neoplastic progression [11].
One understudied member of the ADAM family in human
cancer is ADAM15 disintegrin (ADAM15), which is located
on chromosome 1 at 1q21.3. This region is known to be
amplified in many cancers, including metastatic prostate
cancer (PCa), breast cancer, and melanoma [12,13]. Spe-
cifically, the region of chromosome 1 from 1q21 to 1q23 is
increased in several types of adenocarcinoma and sarco-
mas, and thus appears to be a common aberration in many
human cancers. Reports show that amplification of this
region is higher in advanced metastatic cancers compared
to tissues isolated from primary diseases [14–16].
ADAM15 is thought to serve a dual function in metastasis
by detaching cells from the ECM through its disintegrin domain
and by degrading the ECM through the metalloproteinase
domain. ADAM15 has been shown to degrade collagens I
and IV and to cleave the inflammatory cytokine CD23 [17,18].
ADAM15 has also been shown to influence ECM remodeling
within rheumatoid synovial tissues and in atherosclerosis
[19,20]. Additionally, ADAM15 is believed to interact with
integrins avb3, a5b1, and a9b1 through its disintegrin domain.
Uniquely, ADAM15 is the only family member to encode an
RGD (Arg–Gly–Asp) binding motif, suggesting an important
role in cell attachment and invasion [6,7]. In fact, ADAM15
induces glomerular mesangial cell migration within the kidney
[7] and transactivates EGFR by cleaving the EGFR ligands
amphiregulin and TGF-a in bladder cancer cell lines [21].
Knowledge concerning ADAM15 expression in human
cancer is limited. We initiated the current study to compile
the first comprehensive expression profile of ADAM15 by
using multitumor tissue microarray (TMA) technology. Our
preliminary findings demonstrated a significantly increased
expression of ADAM15 in multiple adenocarcinomas. A
thorough analysis of ADAM15 staining in regard to PCa
and breast cancer, using TMA staining, revealed that the
highest levels of expression correlated with advanced meta-
static diseases, and a clear association with clinical param-
eters was determined.
Materials and Methods
Study Population and Tissue Collection
Formalin-fixed paraffin-embedded tissue blocks with
tumor samples were previously set up for multitumor TMA.
PCa and breast cancer TMAs were identified as part of
the Institutional Review Board–approved project from a tis-
sue bank.
Prostate tissue samples were taken from the radical
prostatectomy series and the Rapid Autopsy Program [22]
at the University of Michigan Prostate Cancer Specialized
Program of Research Excellence (SPORE) Tissue Core
(Ann Arbor, MI). Clinically localized PCa cases were taken
from a cohort of men who underwent radical retropubic
prostatectomy as monotherapy for clinically localized PCa
between January 1995 and December 2001. Tumors were
staged using the tumor–node–metastasis system [23] and
were graded according to the system originally described by
Gleason [24,25]. Snap-frozen prostate samples used for
expression analysis were all evaluated histologically by a
study pathologist (M.A.R.). All samples were trimmed to
ensure that >95% of the sample represented the desired
lesion. Breast cancer tissue samples were selected by a
dedicated pathologist (C.G.K.) and categorized according to
histology (i.e., carcinoma in situ, invasive breast cancer, or
metastatic breast cancer).
cDNA Expression Profiles in PCa cDNA
RNA was isolated from 55 prostate tissue samples.
Construction of cDNA microarrays was described in detail
elsewhere [28]. In brief, plasmid templates for a maximum of
20,000 transcripts were isolated from bacterial clones, and
inserts were amplified by polymerase chain reaction (PCR).
Purified PCR fragments were printed on glass slides and
cross-linked with DNA targets. cDNA generated from 55 PCa
samples included 34 localized PCa and 21 metastatic tissue
samples. These cDNA were labeled with distinguishable
fluorescent dye and hybridized to a cDNA microarray. The
cDNA microarray was analyzed using a scanner, and fluo-
rescence ratios were determined for each gene. Color inten-
sities were converted into ratios of gene expression. These
ratios were inputted into a database for analysis.
TMAs
As preparation for the construction of the TMAs, all glass
slides were examined to identify areas of benign or neoplas-
tic lesions. To optimize transfer to the arrays, target areas
were encircled on a glass slide template. TMAs were as-
sembled using manual tissue array (Beecher Instruments,
Silver Spring, MD), as previously described [26,27]. Tissue
cores from circled areas were targeted for transfer to recip-
ient array blocks. Several replicate tissue cores were sam-
pled from each of the selected tissue types. TMA cores 0.6
mm in diameter were each spaced 0.8 mm from core center
to core center. After construction, 4-mm sections were cut,
and hematoxylin and eosin staining was performed on the
initial slide to verify the histologic diagnosis. TMA images
were acquired using the BLISS Imaging System (Bacus
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Laboratories, Lombard, IL). ADAM15 protein expression was
evaluated in a blinded manner. All images were scored for
ADAM15 protein expression intensity by dedicated patholo-
gists (M.A.R. and C.G.K.).
The tissue specimens on this array were derived from 22
different types of neoplastic tissue (i.e., lung, breast, and
colon cancers). Thus, this array represents a unique source
for evaluating and comparing different tumor types, under the
same conditions, in a very efficient manner. The array con-
sisted of tissue samples of 188 patients. The array was
primarily set up with cores taken only from neoplastic areas.
With several sections having been cut for experiments, 40
samples of the stained array were found to be benign. One
hundred forty-eight samples were confirmed as neoplastic.
PCa TMAs. Two TMAs containing tissues from the pros-
tatectomy series (benign versus localized disease) and from
hormone-refractory PCa (benign versus localized versus
metastatic) from the Rapid Autopsy Program (University of
Michigan, SPORE) were constructed for this study. All TMA
samples were assigned a diagnosis: benign, atrophic, and
high-grade prostatic intraepithelial neoplasia, and PCa. One
hundred sixty-four benign tissue cores, 85 localized PCa, and
82 tissue cores of far advanced metastatic diseases were
suitable for analysis. Of the cases with localized PCa, the
average age at surgery was 61.9 years (minimum = 47 years,
maximum = 76 years). Eleven of 29 had a Gleason score of 5
or 6; the other cases had Gleason scores z7. Mean preop-
erative prostate-specific antigen (PSA) was 15 ng/ml (2.6–
85.7 ng/ml). PSA failure as endpoint was defined as two con-
secutive PSA rises after having reached the nadir of <0.01 ng/
ml after surgery. Mean follow-up timewas 1354 days (median =
1669 days, minimum = 66 days, maximum = 2332 days).
Breast cancer TMA. The total number of patients repre-
sented on the TMAwas 119. The following are the categories
according to tissue type: stroma (n = 80), normal (n = 37),
carcinoma in situ (ductal or lobular, n = 17), invasive carci-
noma (ductal or lobular, n = 66), and metastatic carcinoma
(n = 12). The total number of cases for evaluation after cal-
culating the mean staining intensity for each tissue category
was 212. Of the breast cancer cases, the average age at the
time of diagnosis was 53.9 years (minimum = 29.9 years,
maximum = 83.3 years). The mean tumor size was 2.6 cm
(minimum = 1.0 cm, maximum = 8.0 cm). The mean number
of total nodes removed was 15.7 (maximum = 29); of those,
the mean number of positive nodes was 3.5 (minimum = 0,
maximum = 25). Receptor status was available for the
majority of cases. In this TMA, estrogen receptor (ER)–
negative patients numbered 22, and the ER-positive
patients, numbered 43. Additionally, 31 cases were proges-
terone receptor (PR)–negative and 33 cases were PR-
positive. HER-2/neu was not overexpressed in 46 cases
and was overexpressed only in 14 of these cases. Twenty
of 112 cases had angioinvasion. The mean follow-up time
was 1213 days (median = 719 days, minimum = 29 days,
maximum = 7217 days). Of patients with known status on
follow-up (n = 92), 55 had no evidence of disease, 25 were
alive with recurrence, 6 had died due to breast cancer, and 6
died of other causes.
Immunohistochemistry (IHC) of ADAM15 and tissue
inhibitor of metalloproteinase 2 (TIMP2)
Standard biotin–avidin complex IHC was performed to
evaluate ADAM15 protein expression using a polyclonal anti-
ADAM15 antibody (no. AB19035; Chemicon, Temecula, CA).
Appropriate horseradish peroxidase–conjugated secondary
antibody was obtained from BioRad (Hercules, CA). The
antibody received microwave pretreatment (30 minutes at
100jC in 10 mM citrate buffer) for antigen retrieval. The
reaction time for primary antibody incubation was 120minutes
at ambient temperature. This maybe needed for human sam-
ples, as this antibody was raised against the mouse peptide
and was 85% homologous with human antibodies. The chro-
mogen 3,3-diaminobenzidine tetrahydrochloride was used
to visualize ADAM15-positive staining. Based on previous
works, protein expression was scored as 1 = negative, 2 =
weak, 3 = moderate, and 4 = strong [29,30]. Standard IHC
was equally performed for the evaluation of TIMP2 protein
expression using a monoclonal anti-TIMP2 antibody (no.
MAB3310; Chemicon). Visualization of positive staining for
TIMP2 was performed using the chromogen 3,3-diamino-
benzidine tetrahydrochloride, and protein expression was
scored the same as for ADAM15 staining, as described here.
Cloning and Construction of the ADAM15-Tagged Vector
The cDNA for human ADAM15 and the pCDNA3 vector
containing a hemagglutinin (HA) tag were kind gifts of Carl
Blobel and Gabrielle Nunez, respectively. The cDNA plasmid
containing the hADAM15 sequence was used as template
for PCR reactions. DNA primers that contained BamHI and
XhoI sequences were used to create the PCR product
BamHI/ADAM15/XhoI (5V to 3V). This sequence did not
contain a stop codon [forward ‘‘primer A (BamHI)’’ sequence:
AATACGACTCACTATAGGGAGACCC; reverse ‘‘primer B
(XhoI)’’ sequence: CTCGAGGAGGTAGAGCGAGGA-
CACTGTC]. This BamHI/ADAM15/XhoI DNA was then
cloned into a shuttle vector from the TA Cloning Kit system
(Invitrogen, Carlsbad, CA) prior to ligation into the pCDNA3
vector that contained an HA tag (3V). Next, GFP sequence
was generated as a PCR product that contained XbaI sites at
both the 5 prime and 3 prime ends using the pGFPN-1 vector
as template for this reaction (InVitrogen). The GFP DNA
sequence was inserted in frame into the pCDNA vector at the
3 prime end of the hemaglutanin tagged ADAM15 (ending
with a stop codon), as a second step cloning. This plasmid
DNA was transformed and purified from bacteria. Purified
plasmid DNA encoding the ADAM15-HA-GFP (designated
LNCaP M142) was finally sequenced for verification.
Cell Culture and Transfection of ADAM15 (M142 cDNA)
into LNCaP Cells
The PCa cell line LNCaP was obtained from the American
Type Culture Collection (Manassas, VA). Cells were main-
tained in RPMI 1640 with 8% fetal bovine serum (FBS), 0.1%
glutamine, and 0.1% penicillin/streptomycin (BioWhittaker,
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Walkersville, MD). LNCaP cells were grown to 70% conflu-
ence in serum containing a medium for transfection. TFX50
reagent (Promega, Madison, WI) was used for transfection as
described by the manufacturer, with the following modifica-
tions: 15 mg of M142 DNA and 45 ml of TFX50 reagent were
added to 5ml of serum-freemedia for each dish of cells (grown
in 100-mm culture dishes). This mixture was incubated for
4 hours at 37jC in a cell culture incubator. Following this
incubation of TFX50 and DNA under serum-free conditions,
10 ml of 15% FBS medium was then added to the dishes,
and transfection in the cell incubator continued for a total of
72 hours. On completion of this procedure, the cells were
allowed to recover in the normal growth medium prior to se-
lection into media containing 500 mg/ml G418. Stable cell lines
were selected from pools of G418-resistant LNCaP cells.
Additionally, a final round of selection using FACS sorting
was used to select cells with high fluorescence expression of
the GFP tag. Overexpression of ADAM15-tagged protein was
evaluated byWestern blot analysis using a polyclonal antibody
(no. 19036; Chemicon, Temecula, CA). Results showed a high
expression of exogenous ADAM15 protein and no changes in
growth rate, compared to vector controls (data not shown).
cDNA Microarray Analysis of PCa LNCap M142 Cells
RNA was prepared from the vector control LNCap cells
and from the ADAM15 overexpressing cell line, LNCaP
M142. Because ADAM15 is endogenously expressed in
LNCaP cells, the vector control cell line was used as baseline
for expression in comparison to the LNCap M142 cell line.
RNA from both cell lines were prepared from log-phase
cultures growing in 8% serum-containing culture medium.
Microarray analysis was performed at the University of Ulm
(Ulm, Germany). This microarray procedure has been pre-
viously reported [30].
Statistical Analyses
Statistical analysis was performed using SPSS (SPSS,
Chicago, IL). Primary analysis of cDNA expression data was
performed with Genepix software and Cluster analysis (Mo-
lecular Devices Corp., Downingtown, PA), was performed
with the program Cluster, as described earlier [28,30]. AD-
AM15 expression was statistically evaluated using mean
score results from each case for each tissue type (i.e., loca-
lized PCa and hormone-refractory PCa). To test for sig-
nificant differences in mean ADAM15 protein expression
between all tissue types, Mann-Whitney U test was per-
formed. Mean expression scores for all examined cases
were presented in a graphic format using error bars with
95% confidence interval (CI). For clinically localized PCa
samples, ADAM15 protein expression was evaluated for
association with pathology parameters (i.e., tumor stage)
using t-test and Mann-Whitney U test. Univariable Cox
regression analysis was used to evaluate the risk of PSA
failure following prostatectomy (postsurgical PSA progres-
sion >0.2 ng/ml) and the risk of local or distant recurrence in
breast cancer patients. Multivariable analysis using Cox
hazards regression, with a stepwise backward selection
(Wald), was used to simultaneously evaluate clinical, path-
ological, and molecular parameters. P < .05 was considered
statistically significant.
Results
ADAM15 Expression on Multitumor TMA
To explore the expression of ADAM15 in cancer, we used
the Oncomine database created at the University of Michigan
in the laboratory of A.M. Chinnaiyan [31]. In this database, we
looked at the cDNAexpression arrays of normal versus tumor
cells. We found that ADAM15 was upregulated in many
cancer arrays (see Figure W1). This was intriguing and led
the authors to look at the protein expression of this ADAM
protease in a broad spectrum of solid tumors. Thus, ADAM15
staining was evaluated on a multitumor TMA. Of 22 different
tumor types represented in this TMA, the strongest staining
was observed in tissue samples derived from ovary, breast,
colon, and lung cancers. The lowest staining was observed in
samples derived from pheochromocytoma, sarcoma, thyroid
cancer, and testicular cancer (data not shown). All tumor
tissues had higher expression levels compared to benign
tissue samples (Figure 1A). The mean expression level for
benign tissue was 1.43 [median = 1.00, standard error (SE) =
0.15, standard deviation (SD) = 0.96] compared to 2.19
(median = 2.00, SE = 0.10, SD = 1.26) for tumor tissue sam-
ples. The difference in expression levels was highly signifi-
cant (Mann-Whitney U test, P < .001). Interestingly, when
performing analysis between adenocarcinomas and non-
adenocarcinomas (Figure 1B), we found that ADAM15 ex-
pression was significantly higher in all adenocarcinomas
(mean = 1.78, median = 3.00, SE = 0.17, SD = 1.23) com-
pared to other types of neoplastic tissue (mean = 1.84,
median = 1.00, SE = 0.12, SD = 1.15) (Mann-Whitney U test,
P < .001). Therefore, these data demonstrate that the highest
staining occurred in cancers derived from epithelial lineages.
ADAM15 was found to be overexpressed in adenocarci-
nomas compared to nonadenocarcinomas. Based on this
observation, we then sought to further investigate ADAM15
expression in two of the most common hormone-regulated
adenocarcinomas: PCa and breast cancer.
Expression in PCa cDNA Array
To explore the expression of ADAM15 in PCa progres-
sion, we first examined a PCa cDNA expression array
derived form 103 benign and PCa specimens [28,30]. When
we examined this array for dysregulated proteases, we found
ADAM15 to be significantly overexpressed in PCa (Figure 2).
Tissues were grouped under the following classifications: be-
nign (normal adjacent prostate tissue), clinically localized PCa,
and metastatic PCa. In relation to benign prostate tissues,
localized PCa was significantly upregulated (Mann-Whitney
U test, P < .005; localized PCa mean = 1.15, median = 1.14,
SE = 0.03, SD = 0.24). In addition, there was significant
upregulation in the expression of ADAM15 in metastatic PCa
compared to that in localized PCa cases (Mann-Whitney
U test, P < .003; metastatic PCa mean = 1.37, median = 1.33,
SE = 0.06, SD = 0.28).
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ADAM15 Protein Expression in TMA of PCa
To validate the protein expression of ADAM15 in situ, an
additional cohort of prostate samples from those used in the
cDNA expression array analysis was used. A remarkable
contrast in the levels of ADAM15 protein expression in
malignant epithelia relative to adjacent benign epithelia
was readily apparent. Many of the metastatic PCa samples
demonstrated very strong ADAM15 expression. To assess
ADAM15 protein expression in hundreds of prostate speci-
mens (n = 313), we quantitated TMA data. From benign PCa
(n = 164), localized PCa (n = 85), and metastatic PCa (n =
82), the mean ADAM15 protein staining intensity was deter-
mined to be 1.15 (median = 1.0, SE = 0.03, SD = 0.39), 2.16
(median = 2.0, SE = 0.11, SD = 1.00), and 2.68 (median =
3.00, SE = 0.1, SD = 0.94), respectively. Pairwise compar-
isons demonstrated dramatic differences in staining intensity
between clinically localized PCa with respect to benign
prostate tissues and metastatic hormone-refractory PCa
samples (Mann-Whitney U test, P < .001). These data are
graphically summarized using error bars representing the
95% CI for each tissue category (Figure 2B).
Staining of ADAM15 was then assessed for localized PCa
and for potential associations with clinical and pathological
parameters. The parameters, including age, predictor of PSA
failure, preoperative PSA (and categorized PSA), gland
weight, pathological tumor stage, Gleason score, extrapro-
static extension, multifocality, tumor size, seminal vesicle in-
volvement, and margin status, were examined for their ability
to predict biochemical failure following surgical treatment.
Using univariable Cox regression analysis of ADAM15 ex-
pression, we did not find a strong association with outcome
[P = .26, relative risk (RR) = 1.43]. But when clinical pa-
rameters, including tumor size (P = .05, RR = 2.2), tumor
stage (P = .05, RR = 1.7), seminal vesicle involvement
(P = .006, RR = 2.6), and extraprostatic extension (P = .013,
RR = 5.4), were evaluated, we saw an association with
PSA failure.
We then looked for potential associations between clinical
parameters and ADAM15 protein expression in advanced
PCa disease. Interestingly, Gleason sum (categorized as <7
and z7) was significantly associated with ADAM15 expres-
sion (Mann-Whitney U test, P = .014). This is graphically
demonstrated in Figure 2C. Extraprostatic extension and
tumor stage also showed an association with ADAM15
expression (P < .001 and P = .004), whereas all other clinical
parameters did not (P > .05).
The highest expression of ADAM15 in prostate tissue
samples was observed in hormone-refractory metastatic
PCa when analyzed at the RNA and protein levels. Our re-
sults also indicate that, in localized PCa cases, there is a
strong association with Gleason sum, which is known to cor-
relate with poor disease outcome.
ADAM15 Expression in TMA of Breast Cancer
To validate the protein expression of ADAM15 in breast
cancer, we analyzed a breast cancer TMA consisting of
stroma (n = 80), normal breast tissue (n = 37), and neoplastic
tissue [carcinoma in situ (n = 17), invasive carcinoma (n =
66), and metastatic deposit (n = 12)]. Staining intensities
were compared between malignant epithelia and benign
epithelia or stroma. Once quantified, the expression levels
demonstrated the mean ADAM15 protein staining intensity
for stroma (1.0; median = 1.0, SE = 0.02, SD = 0.16), normal
tissue (1.34; median = 1.00, SE = 0.07, SD = 0.45), carci-
noma in situ (2.85; median = 3.00, SE = 0.21, SD = 0.9),
invasive breast cancer (3.07; median = 3.15, SE = 0.11, SD =
0.91), and metastatic disease (3.28; median = 3.5, SE =
0.25, SD = 0.87). Here, pairwise comparisons demonstrated
highly significant differences in staining intensity between
malignant and benign breast tissues (Mann-Whitney U test,
P < .001). Although metastatic tissue samples had the
highest mean expression levels, the difference between
carcinoma in situ and invasive carcinoma was not significant
(i.e., comparison of invasive ductal or lobular carcinoma
Figure 1. (A) Comparison of benign tissue samples with neoplastic tissue
samples of a multitumor TMA independent of organ site. There is a highly
significant difference (Mann-Whitney U test, P < .001) in the expression
values of ADAM15 between normal and neoplastic tissue samples, with an
overexpression of ADAM15 in neoplastic tissue. (B) Comparison of non-
adenocarcinomas and adenocarcinomas of different origins. There is a highly
significant difference in the protein expression of ADAM15 within these two
categories. In adenocarcinomas, ADAM15 is significantly higher compared to
other types of neoplastic tissue (P < .001).
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versus metastases; P = .3). When the cutoff for staining
intensity was set at 3.0, 42 of 66 (64%) cases of invasive
carcinomas screened positive compared to 10 of 12 (83%)
positive cases of metastatic samples. These results demon-
strate that, although there is no statistically detectable dif-
ference in staining intensity between invasive samples and
metastatic samples, the highest staining was observed in
metastatic cases. Therefore, the trend demonstrates an
increased expression in ADAM15, as the disease pro-
gresses from low-grade, to advanced, to metastatic disease.
The data are graphically summarized for each tissue cate-
gory in Figure 3A.
To parallel our work with prostate array, we then assessed
ADAM15 protein expression in breast tissues for association
with clinical and pathological parameters and as predictor of
disease recurrence. Using univariable Cox regression anal-
ysis of ADAM15 expression, we did not find a strong asso-
ciation with outcome, defined as local or distant recurrence
(P = .517, RR = 1.075, CI = 0.865–1.335). Clinical param-
eters were as follows: tumor stage (P = .877, RR = 1.034,
CI = 0.680–1.571), number of positive nodes (P = .686, RR =
1.01, CI = 0.963–1.059), ER (P = .416, RR = 0.775, CI =
0.419–1.432) or PR (P = .907, RR = 0.963, CI = 0.51–1.82),
and HER-2/neu status (P = .549, RR = 0.913, CI = 0.679–
1.229). In addition, the increase in ADAM15 staining showed
no association with failure during follow-up. At the univari-
ate level, histologic grade (P = .041, RR = 0.512, CI =
0.27–0.973), age at diagnosis (P < .000, RR = 1.044, CI =
1.021–1.068), and tumor size (P = .032, RR = 0.712,
CI = 0.522–0.972) were associated with outcome. In our
patient group, we found a strong association between angio-
invasion and disease-free survival (P = .001, RR= 2.665, CI =
1.522–4.668), which remained significant in a multivariate
analysis (backward stepwise selection; Wald, P = .002).
Additionally, we looked for potential associations between
clinical parameters and ADAM15 protein expression in the
cohort of neoplastic cases. There was no association be-
tween ADAM15 expression levels and parameters such as
tumor stage, size of tumor, grade, number of positive lymph
nodes, ER, PR, and HER-2/neu status (P > .05) compared
within samples of advanced-stage cases. Interestingly, we
found that angioinvasion was associated with high expres-
sion of ADAM15 protein (Mann-Whitney U test, P = .006).
Therefore, patients with angioinvasive breast cancer had a
significantly higher expression of ADAM15. This is graph-
ically demonstrated in Figure 3B. The mean staining inten-
sity of cases with angioinvasion was 3.37 (median = 3.5,
SE = 0.16, SD = 0.72) compared to those without angio-
invasion (mean = 2.72, median = 3.0, SE = 0.11, SD = 0.99).
Figure 2. (A) ADAM15 is significantly overexpressed at the RNA level in
neoplastic prostate tissue. Its expression is significantly higher in localized
PCa than in benign prostatic tissue, and expression is highest in patients in
the hormone-refractory metastatic group. (B) Three hundred twenty-one
tissue samples were evaluated in this TMA. Staining intensity was
significantly stronger in metastatic tissue samples than in localized PCa.
Normal prostate tissue showed very low levels of ADAM15 expression (P <
.001). (C) There is a strong association between ADAM15 expression in the
TMA and Gleason sum categorized as <7 and z7 (P = .014).
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ADAM15 is not expressed in stromal cells and is ex-
pressed at low levels in breast epithelial tissues. In normal
glandular breast tissues, ADAM15 is expressed at the sur-
face of the lumen in a highly polarized fashion. As the dis-
ease progresses to a more advanced stage, this polarized
staining pattern is lost and ADAM15 expression becomes
upregulated and diffused throughout the cytoplasm. Quanti-
fication of breast cancer TMA staining shows that ADAM15
protein expression is highest in cases of invasive breast
cancer and metastatic breast cancer.
Evaluating the Expression of Proteases and Protease
Inhibitors in the Overexpression of ADAM15 by
cDNA Microarray
To determine the gene expression profile of ADAM15
overexpression in a PCa system, we created a stable LNCaP
PCa cell line expressing a tagged ADAM15 protein (M142,
described here). Figure 4, Panel B shows the protein ex-
pression of the ADAM15/GFP fusion protein in the LNCaP
M142 cells under fluorescencemicroscopy. Figure 4 Panel A,
shows the morphology of these same cells under bright
field. By western analysis, we detected the exogenous
ADAM15 protein in less than 2ug of total cell lysate per lane,
(data not shown). This analysis proved that the ADAM15
fusion protein was very highly expressed in these cells in
culture. Once a stable, highly expressing cell line of LNCaP
M142 was established, RNA was isolated, and gene expres-
sion profile was generated on the same cDNA chip as the
PCa profiles, as described in Materials and Methods section.
In this experiment, we compared vector control to M142 cells
in the presence of growth factors. Results showed that
ADAM15 was 1.5-fold overexpressed in stable transfectants
compared to vector control. Another 376 genes or expressed
sequence tags were at least 1.5-fold overexpressed com-
pared to vector control. Two hundred ninety-six genes were
at least 0.5-fold downregulated. It has been previously
published and is an accepted theme in the protease field
that a change in the expression level of a single protease will
then alter the expression of its inhibitor(s), and this change
can additionally influence the expression of other proteases
expressed by that cell [32,33]. Therefore, we focus on and
report here the results of our array data, which show signifi-
cant changes in the expression levels of protease inhibitors
and other proteases affected specifically by the overexpres-
sion of ADAM15 in our LNCaP PCa model. A selection of
these upregulated and dysregulated protease and protease
inhibitor genes is given in Table 1. Interestingly, TIMP2 was
overexpressed in M142 (ADAM15) LNCaP cells (1.7-fold
compared to vector control). To validate this finding, we
stained our tissue samples in the PCa TMA described here
with an antibody against TIMP2.
TIMP2 Staining of PCa TMA
Acknowledging the fact that there are tremendous inter-
actions between ADAMs and metalloproteinases and their
inhibitors, we wanted to evaluate further the overexpression
of TIMP2 in LNCaP M142 cells from a microarray cDNA
experiment. To begin to validate this finding, we analyzed the
protein expression of TIMP2 in a separate PCa TMA. The
expression levels in normal prostatic tissue were compared
to those of localized PCa cases. The result is graphically
given in Figure 5, demonstrating a significant overexpression
(Mann-Whitney U test, P < .001) of TIMP2 in PCa (mean =
Figure 3. (A) Protein expression of ADAM15 in different subtypes of breast
cancer from breast TMA. A significantly higher expression of ADAM15 was
seen in neoplastic samples (P < .001). Within different categories of
malignant subtypes, the differences are not significant. The highest levels of
ADAM15 were present in metastatic breast cancer tissue samples. Examples
of two tissue cores (one from a normal tissue and the other from an invasive
breast carcinoma) are depicted. (B) Breast cancer with angioinvasion has a
significantly higher expression of ADAM15 protein than tissues without
angioinvasion (P = .006).
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3.51, median = 4.0, SD = 0.68) compared to normal tissue
(mean = 2.32, median = 2.0, SD = 1.09), is graphically given
in Figure 4. Based on the results shown in Table 1 and
Figure 5, we hypothesize that there might be an important
interaction between ADAM15 expression and TIMP2 expres-
sion levels in PCa. This interaction may affect a common
protease pathway involved in the progression of advanced
metastatic disease.
Discussion
The ADAM family of proteases was first reported in 1995 [34].
Over the past 10 years, these proteins have been associated
with distinct biologic processes, including reproduction
(sperm/egg fusion), wound healing (migration and adhesion),
inflammation (release of TGF-a), and tissue organogenesis
[34]. More recently, members of the ADAM family have been
implicated in tumorigenesis. This does not seem unreason-
able, as this family of molecules has been associated with
proteolytic activation, adhesion, and release of cytokines,
which promote growth through signal transduction pathways.
Specifically, reports of ADAM15 have implied an associa-
tion with tumorigenesis, but the functional role that ADAM15
plays in this process is not known. Recent reports, primarily
utilizing DNA and RNA platforms, demonstrate increased
expression of ADAM15 in ovary, gastric, lung, and breast
cancer tissues [35–40]. Samples of these same tumors are
represented in TMAs reported in this study and confirm
increased ADAM15 protein expression in patients with ovary,
gastric, lung, and breast cancers.
One of these reports analyzed the expression of ADAM15
in lung cancer cell lines and tissues and found that normal
epithelial cells were negative for ADAM15 expression and
that a higher expression was always found in tumor cells
within the same tissue sections [39]. As observed in our
study, adenocarcinoma of the lung showed the strongest
staining. In comparison, small cell lung cancer showed only
weak ADAM15 expression in our hands.
This report examined the expression of ADAM15 in mul-
tiple types of solid tumors, thus expanding the information
base on ADAM15 expression in cancer. By using TMAs that
included 22 different types of tumors, we can now report that
the ADAM15 protein is upregulated in a variety of tumors but
is most highly expressed in adenocarcinoma. From our TMA
data, we observed that the highest levels of staining in tissue
samples derived from ovary, breast, ileum, colon, and lung
cancers. Lower values for protein expression were found in
pheochromocytoma, sarcoma, carcinoma of the thyroid, and
testicular cancer. In this study, all neoplastic tissue samples,
compared to benign tissue samples, had higher expression
levels, with adenocarcinomas exhibiting the highest level of
ADAM15 staining.
Our previous work demonstrates that proteases play an
important role in changing the homeostatic balance of both
the prostate and breast epithelia [41–44]. In this study, we
continued to focus on these two hormonally sensitive tissues
and explored the expression of the ADAM15 protease in
metastatic disease progression. We first found that ADAM15
was upregulated in many cancer cDNA arrays (see Table W1
generated on the Oncomine website Oncomine.org, includ-
Figure 4. (A) Over-expression of ADAM15 protein in LNCaP cells in culture
where, LNCaP M142 cells are shown under bright field microscopy and (B)
the same field of cells under fluorescence, (magnification for both is 20X).
Note that ADAM15/GFP fusion protein is localized to the cell membranes and
the cell/cell junctions.
Figure 5. Protein expression of TIMP2 in prostate tissues. TIMP2 expression
is significantly higher in PCa compared to normal or benign prostate tissue
(Mann-Whitney U test, P < .001).
Table 1. cDNA Microarray Experiment Showing Genes That Were Upregu-
lated or Downregulated on the cDNA Chip (Comparing cDNA from LNCaP
M142 ADAM15-Overexpressing Cells with cDNA from Control Cells).
GENE ADAM15 Ratio
NOMANCLATURE (Control
LNCaP)
Upregulated Proteases and Inhibitors:
membrane metallo-endopeptidase MME 2.47
enolase 2 (gamma, neuronal) ENO2 2.42
matrix metalloproteinase 24 MMP24 1.79
tissue inhibitor of metalloproteinase 2 TIMP2 1.69
aconitase 1, soluble ACO1 1.68
a disintegrin and metalloproteinase
domain15
ADAM15 1.52
Downregulated Proteases:
caspase 3, apoptosis-related
cysteine protease
CASP3 0.462
disintegrin-like (reprolysin type)
thrombospondin type 1, motif 3
ADAMTS3 0.417
Given is the ratio of ADAM15 transcripts overexpressed in LNCaP M142 cells
to ADAM15 transcripts overexpressed in vector control LNCaP cells.
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ing arrays of prostate and breast cancer). Now we have
determined that the ADAM15 protein is upregulated in ag-
gressive adenocarcinoma, and we suggest that it may play
an essential regulatory role in the metastatic progression of
both prostate and breast cancers.
For PCa, there is only very limited information available in
the literature with respect to ADAM15. Of the metalloprotein-
ases represented in our PCa cDNA expression array [28,30],
only five metalloproteinases were significantly upregulated;
this included three ADAM family proteases. The overexpres-
sion of ADAM15 mRNA in neoplastic prostate tissue was
validated in two other independent cDNA array studies, thus
providing strong evidence that ADAM15 levels are increased
in cancer tissues compared to normal prostatic tissues
[31,45,46]. In the present study, the highest expression of
ADAM15 was observed in hormone-refractory and advanced
metastatic PCa. In cell culture experiments using LNCaP
cells, ADAM15 expression seemed to be independent of
hormonal stimulus (data not shown). Related family mem-
bers (ADAM9 and ADAM10) are thought to be sensitive to
dihydrotestosterone levels, whereas ADAM17 seems to be
repressed by androgens [7]. These results are based on
studies in cell culture with the LNCaP cell line, which may
represent an early stage of PCa disease. It cannot be
excluded that, in the clinical setting and in advanced tumor
stages, hormonal influences may still affect and influence the
expression levels and activities of these disintegrins.
For cases specific to PCa, we demonstrate that, overall,
increased expression of ADAM15 is associated with a more
aggressive phenotype. This hypothesis is supported by the
finding that, in localized PCa cases, there is a strong
association with Gleason sum. Cases with a Gleason sum
higher than 7 showed stronger ADAM15 expression com-
pared to those with a Gleason sum lower than 7. The
Gleason scoring system provides a well-described patholog-
ical parameter [24,25] in PCa disease and has proven to be a
predictive value, and thus is considered as one of the
strongest parameters for the prediction of outcome after
specific therapy in clinical settings [37,38]. The results of
this study suggest that the overexpression of ADAM15 may
represent a more aggressive PCa phenotype.
In breast cancer, we found ADAM15 to be expressed at
lower levels in the stroma and normal tissues, and at the
highest levels in invasive and metastatic samples. This is in
accordance with observations of an increased copy number
of the ADAM15 gene in human breast cancer cell lines [38].
We also observed overexpression in the tumor aspect of
breast tissues, where we found a very striking association
with angioinvasion. This is interesting for three reasons. First,
angioinvasion has been reported as a predictor of disease
progression [49], local recurrence [50], and overall survival
(RR = 4.26) [51]. Second, ADAM15 was recently described
as a potential target for inhibitors of pathological neovascula-
rization in ADAM15-null mice. In this model, neovasculariza-
tion and melanoma tumor cell growth could be suppressed
on this ADAM15 knockout background [52]. Third, human
ADAM15 contains an RGD sequence and has been shown
to interact with avb3 and avb1 integrins, which can drive an
angiogenic response [53]. There are now several reports
linking integrins to angiogenesis [54–56]. These data sug-
gest that ADAM15 could be directly involved in the process
of tumor cell growth through enhancement of angiogenesis.
Taken together, these results suggest that ADAM15 could be
a target for the development of inhibitors of angiogenesis, as
mice carrying a null mutation in ADAM15 are viable and fertile
without any severe pathological phenotypes [52].
In a separate set of experiments, we analyzed ADAM15
overexpression in the PCa cell line LNCaP using cDNA
microarray technology. To uncover coregulators of disease
progression, we examined gene expression profiles follow-
ing the overexpression of ADAM15 in LNCaP M142 cells
compared to vector control. We focused on proteases and
protease inhibitors, which were associated with ADAM15
overexpression. This analysis revealed that the protease in-
hibitor TIMP2 was upregulated in LNCaP M142 cells. Our
observation was verified in our study on protein level using
a TMA of PCa. For technical reasons, TIMP2 staining was
carried out on a separate TMA. Due to the result of the
expression profile and the high number of cases stained for
ADAM15 and TIMP2, we believe that the results are valid and
representative of PCa. The observed overexpression of
TIMP2 has to be interpreted with caution because it is known
that TIMPs are not totally selective for MMPs [57]. So far, of
these endogenous regulators of MMPs, four TIMPs are
known. For example, TIMP3 is believed to inhibit ADAM17
andADAM12. ADAM10 is also inhibited by TIMP3, in addition
to TIMP1 [58,59]. However, not all MMPs seem to be sensi-
tive to TIMPs. For example, ADAM8 and ADAM9 activity is
not blocked by TIMPs [58]. Our data now suggest that TIMP2
may be an inhibitor of ADAM15; this observation warrants
further study in the context of cancer progression. Addition-
ally, we also report that ADAMTS3 and MMP24 cDNA ex-
pression is directly influenced by the overexpression of
ADAM15, and we plan to verify these results on protein levels
in future experiments.
Alternative splicing of primary RNA transcripts contributes
to the functional regulation of many genes that impact normal
and aberrant cellular functions. Spliced variants of ADAM
gene family members have previously been found in several
cancers, including grossly altered ADAM mRNA variants in
breast cancer cells [38]. Although ADAM15 antibody recog-
nition might be affected by some splicing events, ADAM15
splicing has not been investigated in PCa cells or tissues.
To summarize the present study, we can state that
ADAM15 is overexpressed in a series of solid malignant
tumors where the highest levels of expression are observed
in adenocarcinomas of multiple tumor types. Specifically, we
demonstrate that ADAM15 is highly upregulated in prostate
and breast cancers, where the most significant staining was
detected in advanced metastatic disease. For PCa, there is a
strong association between ADAM15 expression and Glea-
son sum. In breast cancer, ADAM15 is significantly overex-
pressed in angioinvasive carcinoma; this observation may
give us the best insight as to how the overexpression of
ADAM15 directly impacts the growth and spread of more
aggressive cancer cells. It is important to note here that
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Gleason sum and angioinvasion are two parameters asso-
ciated with the worst outcome in a clinical course. In experi-
ments wherein we analyze ADAM15 by cDNA expression in
PCa cells that overexpress this disintegrin, we can report that
ADAM15 directly influences the expression levels of specific
protease inhibitors and proteases.
The results shown here demonstrate upregulation and
change in the protein distribution of ADAM15 inmany types of
adenocarcinoma. This suggests that ADAM15 may play an
essential role in the progression to metastatic disease, es-
pecially in cases of prostate and breast cancers. If this proves
to be the case, then ADAM15may serve as a drug target [13]
for the treatment of patients who present with advanced
stages of cancer and more aggressive types of cancer.
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